The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PDCA training.
- Who it may be relevant to
- Registry conditions: Autoimmune Gastritis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Autoimmune gastritis is currently relatively rare in China due to its insidious onset, diverse clinical manifestations involving multiple systems such as digestive, hematological, and nervous systems, and its association with other autoimmune diseases. It can also be complicated by hyperplastic gastric polyps, gastric neuroendocrine tumors, gastric adenocarcinoma, and other diseases, making it prone to clinical misdiagnosis. As a form of gastritis in the post-Helicobacter pylori era, its detection rate has been gradually increasing with the continuous improvement of endoscopic technology in China. Applying the PDCA cycle management in disease diagnosis can significantly improve the detection rate of the disease, benefiting patients. Through the PDCA management model, this study further enhanced gastroenterologists' understanding of this disease from various aspects, aiming to improve the clinical diagnosis of autoimmune gastritis.
Interventions
- Behavioral PDCA training
Improve diagnostic rate
Primary outcome measures
- Diagnostic Accuracy of AIG [Time frame: 4months]
- The suspected diagnosis rate of AIG [Time frame: 4months]
Secondary outcome measures (2)
- Parietal Cell Antibody（PCA） [Time frame: 4months]
- IF-Ab [Time frame: 4months]
Eligibility criteria
Inclusion criteria
Endoscopy center gastroenterologists in our hospital in 2024
Exclusion criteria
Doctors who withdrew from the PDCA management midway and stopped undergoing gastroscopy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Ningbo first hospital — Ningbo
Publications
- Zhu Y, Wang S, Yu Q, Zheng S, Zhang Z, Xu L, Lin P. The Application of the Plan-Do-Check-Act Management Model in Improving the Diagnostic Yield of Autoimmune Gastritis. Dig Dis Sci. 2026 May 6. doi: 10.1007/s10620-026-09956-w. Online ahead of print. PMID 42087017
Identifiers
NCT: NCT06557252 · 2024-091A-01